162 related articles for article (PubMed ID: 17960969)
1. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg I; Skogvoll E; Spigset O
J Clin Psychiatry; 2007 Oct; 68(10):1540-5. PubMed ID: 17960969
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
Bakken GV; Rudberg I; Molden E; Refsum H; Hermann M
Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
[TBL] [Abstract][Full Text] [Related]
3. Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database.
Andersson ML; Björkhem-Bergman L; Lindh JD
Br J Clin Pharmacol; 2011 Jul; 72(1):153-6. PubMed ID: 21651616
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets.
Hole K; Lorentsen SK; Nordby KL; Slettvik M; Sørum IT; Molden E; Haslemo T
Eur J Clin Pharmacol; 2024 Jun; 80(6):839-845. PubMed ID: 38396309
[TBL] [Abstract][Full Text] [Related]
5. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations.
Aichhorn W; Marksteiner J; Walch T; Zernig G; Saria A; Kemmler G
Int Clin Psychopharmacol; 2006 Mar; 21(2):81-5. PubMed ID: 16421458
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders.
Albantakis L; Egberts K; Burger R; Kulpok C; Mehler-Wex C; Taurines R; Unterecker S; Wewetzer C; Romanos M; Gerlach M
Pharmacopsychiatry; 2017 Nov; 50(6):248-255. PubMed ID: 28561203
[No Abstract] [Full Text] [Related]
7. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.
Reimers A; Skogvoll E; Sund JK; Spigset O
J Clin Psychopharmacol; 2005 Aug; 25(4):342-8. PubMed ID: 16012277
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine serum concentrations in psychiatric patients: the influence of comedication.
Hasselstrøm J; Linnet K
Ther Drug Monit; 2004 Oct; 26(5):486-91. PubMed ID: 15385830
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Winter HR; Earley WR; Hamer-Maansson JE; Davis PC; Smith MA
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):81-98. PubMed ID: 18294091
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.
Gerlach M; Hünnerkopf R; Rothenhöfer S; Libal G; Burger R; Clement HW; Fegert JM; Wewetzer Ch; Mehler-Wex C
Pharmacopsychiatry; 2007 Mar; 40(2):72-6. PubMed ID: 17447177
[TBL] [Abstract][Full Text] [Related]
12. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice.
Wittmann M; Hausner H; Köstlbacher A; Hajak G; Haen E
Neuro Endocrinol Lett; 2010; 31(2):203-7. PubMed ID: 20424588
[TBL] [Abstract][Full Text] [Related]
13. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
14. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
Wong YW; Yeh C; Thyrum PT
J Clin Psychopharmacol; 2001 Feb; 21(1):89-93. PubMed ID: 11199955
[TBL] [Abstract][Full Text] [Related]
15. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.
Castberg I; Spigset O
Pharmacopsychiatry; 2007 May; 40(3):107-10. PubMed ID: 17541885
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.
Hefner G; Shams ME; Unterecker S; Falter T; Hiemke C
Psychopharmacology (Berl); 2016 May; 233(9):1695-705. PubMed ID: 26032842
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders.
Jaskiw GE; Thyrum PT; Fuller MA; Arvanitis LA; Yeh C
Clin Pharmacokinet; 2004; 43(14):1025-35. PubMed ID: 15530131
[TBL] [Abstract][Full Text] [Related]
18. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Seeman P; Tallerico T
Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
[TBL] [Abstract][Full Text] [Related]
19. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders.
Strakowski SM; Keck PE; Wong YW; Thyrum PT; Yeh C
J Clin Psychopharmacol; 2002 Apr; 22(2):201-5. PubMed ID: 11910267
[TBL] [Abstract][Full Text] [Related]
20. [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring].
Köhnlein O; Lutz R; Schmauss M; Messer T
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S175-7. PubMed ID: 15570545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
